520 related articles for article (PubMed ID: 7534202)
1. The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation.
Kawabe T; Naka T; Yoshida K; Tanaka T; Fujiwara H; Suematsu S; Yoshida N; Kishimoto T; Kikutani H
Immunity; 1994 Jun; 1(3):167-78. PubMed ID: 7534202
[TBL] [Abstract][Full Text] [Related]
2. CD40 ligand/CD40 deficiency.
Castigli E; Fuleihan R; Ramesh N; Tsitsikov E; Tsytsykova A; Geha RS
Int Arch Allergy Immunol; 1995; 107(1-3):37-9. PubMed ID: 7542090
[TBL] [Abstract][Full Text] [Related]
3. CD40-deficient mice generated by recombination-activating gene-2-deficient blastocyst complementation.
Castigli E; Alt FW; Davidson L; Bottaro A; Mizoguchi E; Bhan AK; Geha RS
Proc Natl Acad Sci U S A; 1994 Dec; 91(25):12135-9. PubMed ID: 7527552
[TBL] [Abstract][Full Text] [Related]
4. In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. I. In vivo expression of CD40 ligand, cytokines, and antibody production delineates sites of cognate T-B cell interactions.
Van den Eertwegh AJ; Noelle RJ; Roy M; Shepherd DM; Aruffo A; Ledbetter JA; Boersma WJ; Claassen E
J Exp Med; 1993 Nov; 178(5):1555-65. PubMed ID: 7693849
[TBL] [Abstract][Full Text] [Related]
5. Immunohistologic analysis of ineffective CD40-CD40 ligand interaction in lymphoid tissues from patients with X-linked immunodeficiency with hyper-IgM. Abortive germinal center cell reaction and severe depletion of follicular dendritic cells.
Facchetti F; Appiani C; Salvi L; Levy J; Notarangelo LD
J Immunol; 1995 Jun; 154(12):6624-33. PubMed ID: 7539026
[TBL] [Abstract][Full Text] [Related]
6. Signaling through CD40 rescues IgE but not IgG or IgA secretion in X-linked immunodeficiency with hyper-IgM.
Saiki O; Tanaka T; Wada Y; Uda H; Inoue A; Katada Y; Izeki M; Iwata M; Nunoi H; Matsuda I
J Clin Invest; 1995 Feb; 95(2):510-4. PubMed ID: 7532185
[TBL] [Abstract][Full Text] [Related]
7. In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. II. Prolonged suppression of the humoral immune response by an antibody to the ligand for CD40, gp39.
Foy TM; Shepherd DM; Durie FH; Aruffo A; Ledbetter JA; Noelle RJ
J Exp Med; 1993 Nov; 178(5):1567-75. PubMed ID: 7693850
[TBL] [Abstract][Full Text] [Related]
8. Differential requirements for expression of CD80/86 and CD40 on B cells for T-dependent antibody responses in vivo.
Lumsden JM; Williams JA; Hodes RJ
J Immunol; 2003 Jan; 170(2):781-7. PubMed ID: 12517941
[TBL] [Abstract][Full Text] [Related]
9. Undetectable CD40 ligand expression on T cells and low B cell responses to CD40 binding agonists in human newborns.
Durandy A; De Saint Basile G; Lisowska-Grospierre B; Gauchat JF; Forveille M; Kroczek RA; Bonnefoy JY; Fischer A
J Immunol; 1995 Feb; 154(4):1560-8. PubMed ID: 7530739
[TBL] [Abstract][Full Text] [Related]
10. CD40 ligand and appropriate cytokines induce switching to IgG, IgA, and IgE and coordinated germinal center and plasmacytoid phenotypic differentiation in a human monoclonal IgM+IgD+ B cell line.
Cerutti A; Zan H; Schaffer A; Bergsagel L; Harindranath N; Max EE; Casali P
J Immunol; 1998 Mar; 160(5):2145-57. PubMed ID: 9498752
[TBL] [Abstract][Full Text] [Related]
11. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome.
Allen RC; Armitage RJ; Conley ME; Rosenblatt H; Jenkins NA; Copeland NG; Bedell MA; Edelhoff S; Disteche CM; Simoneaux DK
Science; 1993 Feb; 259(5097):990-3. PubMed ID: 7679801
[TBL] [Abstract][Full Text] [Related]
12. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome.
Aruffo A; Farrington M; Hollenbaugh D; Li X; Milatovich A; Nonoyama S; Bajorath J; Grosmaire LS; Stenkamp R; Neubauer M
Cell; 1993 Jan; 72(2):291-300. PubMed ID: 7678782
[TBL] [Abstract][Full Text] [Related]
13. Engagement of CD153 (CD30 ligand) by CD30+ T cells inhibits class switch DNA recombination and antibody production in human IgD+ IgM+ B cells.
Cerutti A; Schaffer A; Goodwin RG; Shah S; Zan H; Ely S; Casali P
J Immunol; 2000 Jul; 165(2):786-94. PubMed ID: 10878352
[TBL] [Abstract][Full Text] [Related]
14. B cell immunopoiesis: visualizing the impact of CD40 engagement on the course of T cell-independent immune responses in an Ig transgenic system.
Erickson LD; Vogel LA; Cascalho M; Wong J; Wabl M; Durell BG; Noelle RJ
Eur J Immunol; 2000 Nov; 30(11):3121-31. PubMed ID: 11093126
[TBL] [Abstract][Full Text] [Related]
15. Mice deficient for the CD40 ligand.
Xu J; Foy TM; Laman JD; Elliott EA; Dunn JJ; Waldschmidt TJ; Elsemore J; Noelle RJ; Flavell RA
Immunity; 1994 Aug; 1(5):423-31. PubMed ID: 7882172
[TBL] [Abstract][Full Text] [Related]
16. Memory B cell development but not germinal center formation is impaired by in vivo blockade of CD40-CD40 ligand interaction.
Gray D; Dullforce P; Jainandunsing S
J Exp Med; 1994 Jul; 180(1):141-55. PubMed ID: 7516404
[TBL] [Abstract][Full Text] [Related]
17. Multivalent, but not divalent, antigen receptor cross-linkers synergize with CD40 ligand for induction of Ig synthesis and class switching in normal murine B cells. A redefinition of the TI-2 vs T cell-dependent antigen dichotomy.
Snapper CM; Kehry MR; Castle BE; Mond JJ
J Immunol; 1995 Feb; 154(3):1177-87. PubMed ID: 7529792
[TBL] [Abstract][Full Text] [Related]
18. Role of protein tyrosine kinases and phosphatases in isotype switching: crosslinking CD45 to CD40 inhibits IgE isotype switching in human B cells.
Loh RK; Jabara HH; Ren CL; Fu SM; Vercelli D; Geha RS
Immunol Lett; 1995 Feb; 45(1-2):99-106. PubMed ID: 7542629
[TBL] [Abstract][Full Text] [Related]
19. Hyper IgM syndrome associated with defective CD40-mediated B cell activation.
Conley ME; Larché M; Bonagura VR; Lawton AR; Buckley RH; Fu SM; Coustan-Smith E; Herrod HG; Campana D
J Clin Invest; 1994 Oct; 94(4):1404-9. PubMed ID: 7523449
[TBL] [Abstract][Full Text] [Related]
20. Induction of Ig somatic hypermutation and class switching in a human monoclonal IgM+ IgD+ B cell line in vitro: definition of the requirements and modalities of hypermutation.
Zan H; Cerutti A; Dramitinos P; Schaffer A; Li Z; Casali P
J Immunol; 1999 Mar; 162(6):3437-47. PubMed ID: 10092799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
